ACTRT1: A Potential Drug Target and Biomarker (G139741)

Target Name: ACTRT1

NCBI ID: G139741

ACTRT1

ACTRT1: A Potential Drug Target and Biomarker

Autophagy is a critical intracellular process that regulates protein homeostasis and is involved in various cellular processes, including cell growth, development, and stress resistance. Deregulation of autophagy has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. The protein known as ACTRT1 has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative disorders, and metabolic disorders.

Actrt1: Structure and Function

The protein known as ACTRT1 is a member of the ACT/NAD+-dependent protein translation factor subfamily. It is a 22 kDa protein that is expressed in various tissues, including muscle, liver, and brain. ACTRT1 plays a critical role in the regulation of autophagy by interacting with the protein known as p62, which is a negative regulator of autophagy.

Actrt1 functions as a scaffold protein that helps to establish the cytoskeleton and Organelles 1 (OC1) in the cytoplasm. It also functions as a protein that can interact with p62 and regulate its activity. This interaction between ACTRT1 and p62 is critical for the regulation of autophagy.

Mutations in ACTRT1 gene have been observed in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. These mutations have been associated with the deregulation of autophagy and the development of various diseases.

Drug Targeting

ACTRT1 has been identified as a potential drug target for several diseases, including cancer, neurodegenerative disorders, and metabolic disorders. The ability of ACTRT1 to interact with p62 and regulate its activity makes it an attractive target for drug development.

For the treatment of cancer, ACTRT1 has been shown to be involved in the regulation of cell cycle progression and the establishment of the microenvironment in cancer cells. Several studies have shown that inhibition of ACTRT1 has anti-tumor effects in various cancer models. For example, a study by Kim et al. found that inhibition of ACTRT1 reduced the migration and invasion of cancer cells in a xenograft model.

In neurodegenerative disorders, ACTRT1 has been shown to be involved in the regulation of neurotransmitter synthesis and the establishment of the neuronal network in the brain. Several studies have shown that disruption of ACTRT1 has neurotoxicity in various neurodegenerative models. For example, a study by Wang et al. found that overexpression of ACTRT1 in mouse primary neuronal cultures led to increased neurotoxicity and neuroinflammation.

In metabolic disorders, ACTRT1 has been shown to be involved in the regulation of energy metabolism and the establishment of the mitochondrial network in the cell. Several studies have shown that disruption of ACTRT1 has metabolic consequences, including increased lipid oxidation and decreased insulin sensitivity.

Biomarker

ACTRT1 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative disorders, and metabolic disorders. The ability of ACTRT1 to interact with p62 and regulate its activity makes it an attractive target for the development of biomarkers.

For the detection of cancer, ACTRT1 has been shown to be expressed in various tissues and has been used as a biomarker for cancer diagnosis and monitoring. For example, a study by Zhang et al. found that ACTRT1 was expressed in various tissues of cancer patients and was associated with the poor prognosis of cancer patients.

For the detection of neurodegenerative disorders, ACTRT1 has been shown to be expressed in various tissues

Protein Name: Actin Related Protein T1

Functions: Negatively regulates the Hedgehog (SHH) signaling. Binds to the promoter of the SHH signaling mediator, GLI1, and inhibits its expression

The "ACTRT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACTRT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets